-transparent.png){kind=logo}
Advances in the immunological identification of primitive haematopoietic cells have led to the development of various techniques for their characterisation and purification. The expression of the CD34 antigen by the stem cell compartment has been exploited for these purposes. Separation systems capable of isolating CD34+ cells on a large scale are finding use in the clinic. Areas of interest overlap for both researchers and clinicians, and efforts to mobilise, characterise, purify and transplant these cells continue. Different CD34 purification systems are reviewed, focusing on their possible applications in different research fields. Clinical results of CD34+ selection and the possible future applications of this technology in the clinic are also reported.
G Nadali, and
E A de Wynter, and
N G Testa
January 1992,
Critical reviews in oncogenesis,
G Nadali, and
E A de Wynter, and
N G Testa
November 2007,
Annales pharmaceutiques francaises,
G Nadali, and
E A de Wynter, and
N G Testa
July 2009,
Cancer immunology, immunotherapy : CII,
G Nadali, and
E A de Wynter, and
N G Testa
February 2006,
Bulletin de l'Academie nationale de medecine,
G Nadali, and
E A de Wynter, and
N G Testa
February 1999,
Drug discovery today,
G Nadali, and
E A de Wynter, and
N G Testa
January 2000,
Journal of neurology, neurosurgery, and psychiatry,
G Nadali, and
E A de Wynter, and
N G Testa
September 2019,
Journal of hematology & oncology,
G Nadali, and
E A de Wynter, and
N G Testa
March 1977,
Archives of pathology & laboratory medicine,
G Nadali, and
E A de Wynter, and
N G Testa
July 2015,
Journal of the Formosan Medical Association = Taiwan yi zhi,
G Nadali, and
E A de Wynter, and
N G Testa
January 2008,
Biochimie,
